Role of Population Based Studies in Advancing Our Knowledge of Myelodysplastic Syndromes

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Date 2025 Jan 17

PMID 39821758

Authors

Diego A Adrianzen-Herrera

Aneta Strumlowska

Affiliations

Soon will be listed here.

Abstract

Purpose Of The Review: Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by high molecular and genomic heterogeneity. Accordingly, efforts in risk assessment and therapeutic intervention mostly target unique profiles that individualize specific MDS subtypes. In this review, we explored the contributions of population based studies accounting for MDS as a group.

Recent Findings: Large population based studies have been critical to define important details of our current knowledge of the disease. We summarized the most important population research contributions in MDS, focusing on its epidemiology, population risk factors, and relevant clinical associations. We discuss how these population data can provide vital insights to inform prevention measures, testing strategies, and treatment decisions. Population studies play an important role in guiding clinical and research efforts in MDS. Despite its complex molecular and genomic landscape, population data is integral to define the burden of disease, identify risk factors and clinical associations, and can help elucidate pathogenic mechanisms.

References

Cazzola M . Myelodysplastic Syndromes. N Engl J Med. 2020; 383(14):1358-1374. DOI: 10.1056/NEJMra1904794. View

Goldberg S, Chen E, Corral M, Guo A, Mody-Patel N, Pecora A . Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010; 28(17):2847-52. DOI: 10.1200/JCO.2009.25.2395. View

Pang W, Pluvinage J, Price E, Sridhar K, Arber D, Greenberg P . Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2013; 110(8):3011-6. PMC: 3581956. DOI: 10.1073/pnas.1222861110. View

Garcia-Manero G . Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023; 98(8):1307-1325. DOI: 10.1002/ajh.26984. View

Platzbecker U, Kubasch A, Homer-Bouthiette C, Prebet T . Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021; 35(8):2182-2198. PMC: 8324480. DOI: 10.1038/s41375-021-01265-7. View

Sekeres M, Taylor J . Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA. 2022; 328(9):872-880. DOI: 10.1001/jama.2022.14578. View

Zeidan A, Shallis R, Wang R, Davidoff A, Ma X . Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2018; 34:1-15. DOI: 10.1016/j.blre.2018.09.001. View

Cogle C . Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep. 2015; 10(3):272-81. PMC: 4553145. DOI: 10.1007/s11899-015-0269-y. View

Cogle C, Craig B, Rollison D, List A . Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011; 117(26):7121-5. PMC: 3143554. DOI: 10.1182/blood-2011-02-337964. View

10.

Bejar R, Steensma D . Recent developments in myelodysplastic syndromes. Blood. 2014; 124(18):2793-803. DOI: 10.1182/blood-2014-04-522136. View

11.

Vardiman J, Lee Harris N, Brunning R . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100(7):2292-302. DOI: 10.1182/blood-2002-04-1199. View

12.

Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-51. DOI: 10.1182/blood-2009-03-209262. View

13.

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

14.

Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley J . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719. PMC: 9252913. DOI: 10.1038/s41375-022-01613-1. View

15.

Saarni M, LINMAN J . Preleukemia. The hematologic syndrome preceding acute leukemia. Am J Med. 1973; 55(1):38-48. DOI: 10.1016/0002-9343(73)90148-4. View

16.

Ma X . Epidemiology of myelodysplastic syndromes. Am J Med. 2012; 125(7 Suppl):S2-5. PMC: 3394456. DOI: 10.1016/j.amjmed.2012.04.014. View

17.

Sekeres M . The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010; 24(2):287-94. DOI: 10.1016/j.hoc.2010.02.011. View

18.

Rotter L, Shimony S, Ling K, Chen E, Shallis R, Zeidan A . Epidemiology and Pathogenesis of Myelodysplastic Syndrome. Cancer J. 2023; 29(3):111-121. DOI: 10.1097/PPO.0000000000000665. View

19.

Guralnik J, Eisenstaedt R, Ferrucci L, Klein H, Woodman R . Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004; 104(8):2263-8. DOI: 10.1182/blood-2004-05-1812. View

20.

Buckstein R, Jang K, Friedlich J, Zhang L, Reis M, Chesney A . Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows. Leuk Res. 2009; 33(10):1313-8. DOI: 10.1016/j.leukres.2009.02.010. View